HDAC Inhibition to Prime Immune Checkpoint Inhibitors

Immunotherapy has made a breakthrough in medical oncology with the approval of several immune checkpoint inhibitors in clinical routine, improving overall survival of advanced cancer patients with refractory disease. However only a minority of patients experience a durable response with these agents...

Full description

Saved in:

Bibliographic Details
Published in:	Cancers Vol. 14; no. 1; p. 66
Main Authors:	Borcoman, Edith, Kamal, Maud, Marret, Grégoire, Dupain, Celia, Castel-Ajgal, Zahra, Le Tourneau, Christophe
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 23-12-2021 MDPI
Subjects:	Apoptosis Cancer therapies Cell cycle DNA methylation Drug development Drugs Enzymes Epigenetics Gene expression Histone deacetylase Immune checkpoint inhibitors Immune response Immunosuppressive agents Immunotherapy Kinases Ligands Lymphoma Medical prognosis Mutation Oncology Patients Proteins Review Signal transduction Tumorigenesis Tumors HDAC inhibitor combination therapies epigenetics immunotherapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!